Journal of Clinical Oncology, Vol 10, 912-922, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience

JD Hainsworth, DH Johnson and FA Greco
Division of Oncology, Vanderbilt University Medical Center, Nashville, TN 37232-5536.

PURPOSE: We previously reported excellent responses to cisplatin-based chemotherapy in a minority of patients with poorly differentiated carcinoma (PDC) or poorly differentiated adenocarcinoma (PDA) of unknown primary site. We have continued to study and to treat these patients, and now report clinical characteristics, treatment results, and prognostic factors in a large group of patients identified prospectively. PATIENTS AND METHODS: Between February 1978 and December 1989, we treated 220 patients with PDC or PDA of unknown primary site. The median age was 39 years; 48% of patients had predominant tumor location in the mediastinum, retroperitoneum, or peripheral lymph nodes. Specialized pathologic studies resulted in the identification of specific tumor types in only a few cases. All patients received cisplatin-based chemotherapy; between 1978 and 1984, 116 patients received cisplatin, vinblastine, and bleomycin (PVeB) +/- doxorubicin, and 104 patients treated since January 1985 received cisplatin and etoposide +/- bleomycin. RESULTS: One hundred thirty-eight patients (63%) had objective responses to therapy, and 58 (26%) had complete response. Thirty-six patients (16%) are currently disease-free at a median of 61 months following therapy (range, 11 to 142 months). Actuarial 10-year survival is 16%. Favorable prognostic factors identified by Cox regression analysis include: (1) predominant tumor location in the retroperitoneum or peripheral lymph nodes, (2) tumor limited to one or two metastatic sites, (3) no history of cigarette use, and (4) younger age. CONCLUSION: Patients with PDC or PDA of unknown primary site represent another group of patients for whom potentially curative therapy is available. Patients with this syndrome should be distinguished from patients with well-differentiated adenocarcinoma of unknown primary site, and should receive a trial of cisplatin-based chemotherapy.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. D. Hainsworth, D. R. Spigel, C. Farley, D. S. Thompson, D. L. Shipley, and F. A. Greco Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network J. Clin. Oncol., May 1, 2007; 25(13): 1747 - 1752. [Abstract] [Full Text] [PDF]

				Y. H. Park, B.-Y. Ryoo, S.-J. Choi, S. H. Yang, and H.-T. Kim A Phase II Study of Paclitaxel plus Cisplatin Chemotherapy in an Unfavourable Group of Patients with Cancer of Unknown Primary Site Jpn. J. Clin. Oncol., November 1, 2004; 34(11): 681 - 685. [Abstract] [Full Text] [PDF]

				D. M. Mintzer, M. Warhol, A.-M. Martin, and G. Greene Cancer of Unknown Primary: Changing Approaches. A Multidisciplinary Case Presentation from the Joan Karnell Cancer Center of Pennsylvania Hospital Oncologist, June 1, 2004; 9(3): 330 - 338. [Abstract] [Full Text] [PDF]

				C. Balana, J.-L. Manzano, I. Moreno, B. Cirauqui, A. Abad, A. Font, J.-L. Mate, and R. Rosell A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site Ann. Onc., September 1, 2003; 14(9): 1425 - 1429. [Abstract] [Full Text] [PDF]

				S. Culine, A. Kramar, M. Saghatchian, R. Bugat, T. Lesimple, A. Lortholary, Y. Merrouche, A. Laplanche, and K. Fizazi Development and Validation of a Prognostic Model to Predict the Length of Survival in Patients With Carcinomas of an Unknown Primary Site J. Clin. Oncol., December 15, 2002; 20(24): 4679 - 4683. [Abstract] [Full Text] [PDF]

				J. D. Hainsworth, W. J. Lennington, and F. A. Greco Overexpression of Her-2 in Patients With Poorly Differentiated Carcinoma or Poorly Differentiated Adenocarcinoma of Unknown Primary Site J. Clin. Oncol., February 1, 2000; 18(3): 632 - 632. [Abstract] [Full Text] [PDF]

				P. W. Kantoff and E. Oliva Case 1-2000- A 27-Year-Old Man with a Painful Retroperitoneal Mass N. Engl. J. Med., January 13, 2000; 342(2): 115 - 122. [Full Text] [PDF]

				K. R. Hess, M. C. Abbruzzese, R. Lenzi, M. N. Raber, and J. L. Abbruzzese Classification and Regression Tree Analysis of 1000 Consecutive Patients with Unknown Primary Carcinoma Clin. Cancer Res., November 1, 1999; 5(11): 3403 - 3410. [Abstract] [Full Text] [PDF]

				G. J. Bosl and R. J. Motzer Testicular Germ-Cell Cancer N. Engl. J. Med., July 24, 1997; 337(4): 242 - 254. [Full Text] [PDF]

				J. D. Hainsworth Treating Advanced Cancer in an Era of Increasing Cost Consciousness Arch Intern Med, October 23, 1995; 155(19): 2035 - 2036. [Abstract] [PDF]

				D. V. Schapira and A. R. Jarrett The Need to Consider Survival, Outcome, and Expense When Evaluating and Treating Patients With Unknown Primary Carcinoma Arch Intern Med, October 23, 1995; 155(19): 2050 - 2054. [Abstract] [PDF]

				J. D. Hainsworth and F. A. Greco Treatment of Patients with Cancer of an Unknown Primary Site N. Engl. J. Med., July 22, 1993; 329(4): 257 - 263. [Full Text]